Search

Displaying results 5031 - 5040 of 8010 in total
  1. Drug

    S-40503

    go.drugbank.com/drugs/DB13938
    Experimental

    S-40503 is an investigational selective androgen receptor modulator (SARM) developed for the treatment of osteoporosis by the Japanese company Kaken Pharmaceuticals.

  2. Drug

    AAV-dXIAP

    go.drugbank.com/drugs/DB17880
    Experimental

    AAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.

  3. Drug

    Penbutolol

    go.drugbank.com/drugs/DB01359
    ApprovedInvestigationalWithdrawn

    This binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy.

  4. Drug

    Glutethimide

    go.drugbank.com/drugs/DB01437
    ApprovedIllicit

    Its use has been largely superseded by other drugs.

  5. Drug

    Cinnamyl alcohol

    go.drugbank.com/drugs/DB14186
    Approved

    Cinnamyl alcohol is a naturally occurring compound that is found within cinnamon. Due to the low levels found in cinnamon, cinnamyl alcohol is usually supplied as DB14184 within commercial products. Cinnamyl alcohol has been shown to be ...

  6. Drug

    VTP-201227

    go.drugbank.com/drugs/DB05652
    Experimental

    It is being developed by Vitae Pharmaceuticals. … VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications.

  7. Drug

    Talniflumate

    go.drugbank.com/drugs/DB09295
    Investigational

    Phase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this … Talniflumate has been approved for approximately 20 years in Argentina other countries (excluding the United States, Europe, and Japan) [L1405].

  8. Drug

    ABX1100

    go.drugbank.com/drugs/DB17655
    Investigational

    It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.[L45978] … ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle.

  9. Drug

    Amolimogene bepiplasmid

    go.drugbank.com/drugs/DB04904
    Investigational

    Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.

  10. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]